Optimising low-dose methotrexate for rheumatoid arthritis-A review

被引：47

作者：

Lucas, Catherine J. ^{[1
,2
,3
]}

Dimmitt, Simon B. ^{[1
,4
]}

Martin, Jennifer H. ^{[1
,2
,3
]}

机构：

[1] Univ Newcastle, Sch Med & Publ Hlth, Discipline Clin Pharmacol, Newcastle, NSW, Australia

[2] Hunter Med Res Inst, Newcastle, NSW, Australia

[3] Hunter New England Local Hlth Dist, Newcastle, NSW, Australia

[4] Univ Western Australia, Fac Hlth & Med Sci, Med Sch, Div Internal Med, Nedlands, WA, Australia

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2019年 / 85卷 / 10期

关键词：

clinical pharmacology; methotrexate; pharmacodynamics; pharmacokinetics; prescribing; rheumatoid arthritis; MODIFYING ANTIRHEUMATIC DRUGS; PULSE METHOTREXATE; SUBCUTANEOUS METHOTREXATE; ORAL METHOTREXATE; DISEASE-ACTIVITY; DOUBLE-BLIND; RISK-FACTORS; POLYGLUTAMATE CONCENTRATIONS; COMBINATION THERAPY; AMERICAN-COLLEGE;

D O I：

10.1111/bcp.14057

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.

引用

页码：2228 / 2234

页数：7

共 95 条

[1] METHOTREXATE IN RHEUMATOID-ARTHRITIS - TOXIC EFFECTS AS THE MAJOR FACTOR IN LIMITING LONG-TERM TREATMENT
ALARCON, GS
TRACY, IC
BLACKBURN, WD
[J]. ARTHRITIS AND RHEUMATISM, 1989, 32 (06): : 671 - 676
[2] Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states
Aletaha, D
Ward, MM
Machold, KP
Nell, VPK
Stamm, T
Smolen, JS
[J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : 2625 - 2636
[3] Diagnosis and Management of Rheumatoid Arthritis A Review
Aletaha, Daniel
Smolen, Josef S.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (13): : 1360 - 1372
[4] WEEKLY PULSE METHOTREXATE IN RHEUMATOID-ARTHRITIS - CLINICAL AND IMMUNOLOGICAL EFFECTS IN A RANDOMIZED, DOUBLE-BLIND-STUDY
ANDERSEN, PA
WEST, SG
ODELL, JR
VIA, CS
CLAYPOOL, RG
KOTZIN, BL
[J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) : 489 - 496
[5] Australian Rheumatology Association, 2016, GUID PRESCR LOW DOS
[6] Methotrexate Catabolism to 7-Hydroxymethotrexate in Rheumatoid Arthritis Alters Drug Efficacy and Retention and Is Reduced by Folic Acid Supplementation
Baggott, Joseph E.
Morgan, Sarah L.
[J]. ARTHRITIS AND RHEUMATISM, 2009, 60 (08): : 2257 - 2261
[7] Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study
Baghdadi, Leena R.
Woodman, Richard J.
Shanahan, E. Michael
Wiese, Michael D.
Mangoni, Arduino A.
[J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2018, 11 : 205 - 210
[8] Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis
Bannwarth, B
Pehourcq, F
Schaeverbeke, T
Dehais, J
[J]. CLINICAL PHARMACOKINETICS, 1996, 30 (03) : 194 - 210
[9] Analysis of Intracellular Methotrexate Polyglutamates in Patients With Juvenile Idiopathic Arthritis Effect of Route of Administration on Variability in Intracellular Methotrexate Polyglutamate Concentrations
Becker, Mara L.
van Haandel, Leon
Gaedigk, Roger
Lasky, Andrew
Hoeltzel, Mark
Stobaugh, John
Leeder, J. Steven
[J]. ARTHRITIS AND RHEUMATISM, 2010, 62 (06): : 1803 - 1812
[10] Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients
Bergstra, S. A.
Allaart, C. F.
Stijnen, T.
Landewe, R. B. M.
[J]. ARTHRITIS CARE & RESEARCH, 2017, 69 (10) : 1473 - 1483

← 1 2 3 4 5 6 7 8 9 10 →